Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 1140 (Primary) ; CDX 301 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; B-cell lymphoma; Bladder cancer; Carcinoma; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Follicular lymphoma; Gastric cancer; Head and neck cancer; Liver cancer; Lymphoma; Malignant melanoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man
  • Acronyms Keynote-A23
  • Sponsors Celldex Therapeutics Inc

    • Most Recent Events

    • 27 Sep 2022 Status changed from active, no longer recruiting to completed.
    • 25 Apr 2022 Status changed from recruiting to active, no longer recruiting.
    • 09 Sep 2021 Planned End Date changed from 1 Nov 2021 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top